AstraZeneca’s oncology R&D chief Susan Galbraith highlights their next-gen prospects at #AACR22
AstraZeneca’s turnaround story rests on the success of 3 big cancer drugs: Lynparza, Tagrisso and more recently Enhertu. So what’s the future all about?
The Big Pharma’s oncology R&D chief Susan Galbraith arrived at AACR this year with dozens of presentations on the early-stage oncology pipeline. And she flagged a few of these as potential next-gen approaches that could help change cancer treatment in the years ahead.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.